Physician profile
Massala Reffell
NPI 1467648881
$6,601.38
in general payments reported to CMS, 2019-2025
29 companies · $1,316 in 2025
The $1,316 reported for 2025 was more than what 94% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $878 · 2020: $278 · 2021: $797 · 2022: $579 · 2023: $1,979 · 2024: $775 · 2025: $1,316.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,069.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,069.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $802.76 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Biotissue Holdings INC. | $728.45 | 2019-2025 | |
| Dompe US, INC. | $722.88 | 2023-2025 | Oxervate |
| Abbvie INC. | $704.01 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $317.50 | 2019-2023 | |
| Aerie Pharmaceuticals, INC. | $272.40 | 2019-2021 | |
| Astellas Pharma US INC | $269.99 | 2023-2025 | Izervay |
| Regeneron Healthcare Solutions, INC. | $253.82 | 2023-2025 | Eylea Hd |
| Tearlab Corp | $249.07 | 2023 | Tearlab Osmolarity System |
| Apellis Pharmaceuticals, INC. | $243.89 | 2023-2024 | Syfovre |
| Genentech USA, INC. | $196.08 | 2019-2023 | Vabysmo |
| Sun Pharmaceutical Industries INC. | $188.41 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $175.17 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $171.24 | 2025 | Xdemvy |
| Merz Pharmaceuticals, LLC | $164.33 | 2023 | Xeomin |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $163.63 | 2021-2023 | Hydrus Microstent, Rocklatan |
| Kala Pharmaceuticals, INC. | $144.26 | 2019 | |
| Alimera Sciences, INC. | $141.94 | 2022-2023 | Iluvien |
| Eyevance Pharmaceuticals LLC | $140.50 | 2020-2021 | |
| Allergan, INC. | $139.40 | 2019-2021 | |
| Ani Pharmaceuticals, INC. | $115.39 | 2025 | Purified Cortrophin Gel |
| Oyster Point Pharma, INC. | $105.69 | 2022-2023 | Tyrvaya |
| Lombart Brothers, INC. | $60.28 | 2023 | Opd-III |
| Mallinckrodt Enterprises LLC | $32.49 | 2019 | |
| Merz North America, INC. | $23.29 | 2019 | |
| Mallinckrodt Hospital Products INC. | $21.22 | 2020 | |
| Shire North American Group INC | $18.41 | 2019 | |
| Coopervision INC. | $17.64 | 2022 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Massala Reffell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.